{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:08Z","timestamp":1792782668288,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Provincial Academic and Technical Support Funding Project","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}]},{"name":"Sichuan Provincial Academic and Technical Support Funding Project","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}]},{"name":"Sichuan Provincial Academic and Technical Support Funding Project","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}]},{"name":"Sichuan Provincial Academic and Technical Support Funding Project","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}]},{"name":"Sichuan Provincial Academic and Technical Support Funding Project","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00277-024-05646-7","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:02:26Z","timestamp":1707350546000},"page":"1197-1209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study"],"prefix":"10.1007","volume":"103","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9711","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"5646_CR1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E et al (2017) Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol 96:1993\u20132003. https:\/\/doi.org\/10.1007\/s00277-017-3150-3","journal-title":"Ann Hematol"},{"key":"5646_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135:2137\u20132145. https:\/\/doi.org\/10.1182\/blood.2020004856","journal-title":"Blood"},{"key":"5646_CR3","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 30:2670\u20132677. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5646_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"key":"5646_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216\u2013228. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X","journal-title":"Lancet Oncol"},{"key":"5646_CR6","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M et al (2021) Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 5:5565\u20135573. https:\/\/doi.org\/10.1182\/bloodadvances.2021005538","journal-title":"Blood Adv"},{"key":"5646_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"5646_CR8","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR et al (2020) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7:e724\u2013e736. https:\/\/doi.org\/10.1016\/S2352-3026(20)30210-6","journal-title":"Lancet Haematol"},{"key":"5646_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"5646_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451\u2013458. https:\/\/doi.org\/10.1111\/j.1365-2141.1976.tb03563.x","journal-title":"Br J Haematol"},{"key":"5646_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A et al (2020) Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov 10:536\u2013551. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710","journal-title":"Cancer Discov"},{"key":"5646_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41698-021-00209-9","volume":"5","author":"BS White","year":"2021","unstructured":"White BS, Khan SA, Mason MJ et al (2021) Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. NPJ Precis Oncol 5:71. https:\/\/doi.org\/10.1038\/s41698-021-00209-9","journal-title":"NPJ Precis Oncol"},{"key":"5646_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0091-679x(04)75028-1","volume":"75","author":"W Gorczyca","year":"2004","unstructured":"Gorczyca W (2004) Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML). Methods Cell Biol 75:665\u2013677. https:\/\/doi.org\/10.1016\/s0091-679x(04)75028-1","journal-title":"Methods Cell Biol"},{"key":"5646_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanm\u00e4ki","year":"2020","unstructured":"Kuusanm\u00e4ki H, Lepp\u00e4 A-M, P\u00f6l\u00f6nen P et al (2020) Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105:708\u2013720. https:\/\/doi.org\/10.3324\/haematol.2018.214882","journal-title":"Haematologica"},{"key":"5646_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/mc.23600","volume":"62","author":"L Zong","year":"2023","unstructured":"Zong L, Yin M, Kong J et al (2023) Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. Mol Carcinog 62:1572\u20131584. https:\/\/doi.org\/10.1002\/mc.23600","journal-title":"Mol Carcinog"},{"key":"5646_CR16","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","volume":"4","author":"B Snijder","year":"2017","unstructured":"Snijder B, Vladimer GI, Krall N et al (2017) Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol 4:e595\u2013e606. https:\/\/doi.org\/10.1016\/S2352-3026(17)30208-9","journal-title":"Lancet Haematol"},{"key":"5646_CR17","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki H, Kyt\u00f6l\u00e4 S, V\u00e4nttinen I et al (2023) Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108:1768\u20131781. https:\/\/doi.org\/10.3324\/haematol.2022.281692","journal-title":"Haematologica"},{"key":"5646_CR18","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 A-M, Renders S et al (2023) Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax. Cancer Discov 13:1408\u20131427. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0939","journal-title":"Cancer Discov"},{"key":"5646_CR19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"5646_CR20","unstructured":"EQUATOR Network | Enhancing the QUAlity and Transparency Of Health Research. https:\/\/www.equator-network.org\/. Accessed 28 Sep 2023"},{"key":"5646_CR21","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 21:4642\u20134649. https:\/\/doi.org\/10.1200\/JCO.2003.04.036","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5646_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cll.2017.07.004","volume":"37","author":"J Xu","year":"2017","unstructured":"Xu J, Jorgensen JL, Wang SA (2017) How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia? Clin Lab Med 37:787\u2013802. https:\/\/doi.org\/10.1016\/j.cll.2017.07.004","journal-title":"Clin Lab Med"},{"key":"5646_CR23","unstructured":"(2017) Common Terminology Criteria for Adverse Events (CTCAE).\u00a0https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"5646_CR24","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.1182\/blood-2022-164984","volume":"140","author":"H Jiang","year":"2022","unstructured":"Jiang H, Wei X, Chang C et al (2022) Phase I study of TQB3455, a selective inhibitor of IDH2 with favorable safety and more potent efficacy to IDH2-R172K mutation, for acute myeloid leukemia and myelodysplastic syndrome. Blood 140:9082\u20139083. https:\/\/doi.org\/10.1182\/blood-2022-164984","journal-title":"Blood"},{"key":"5646_CR25","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 39:2768\u20132778. https:\/\/doi.org\/10.1200\/JCO.20.03736","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5646_CR26","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","volume":"9","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez CA, Reville PK, Kantarjian H et al (2022) Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9:e350\u2013e360. https:\/\/doi.org\/10.1016\/S2352-3026(22)00076-X","journal-title":"Lancet Haematol"},{"key":"5646_CR27","first-page":"124","volume":"10","author":"JM Brandwein","year":"2020","unstructured":"Brandwein JM, Saini L, Geddes MN et al (2020) Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study. Am J Blood Res 10:124\u2013133","journal-title":"Am J Blood Res"},{"key":"5646_CR28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood"},{"key":"5646_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A et al (2021) Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol 96:208\u2013217. https:\/\/doi.org\/10.1002\/ajh.26039","journal-title":"Am J Hematol"},{"key":"5646_CR30","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A et al (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103:e404\u2013e407. https:\/\/doi.org\/10.3324\/haematol.2018.188094","journal-title":"Haematologica"},{"key":"5646_CR31","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE et al (2023) A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov 13:2032\u20132049. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297","journal-title":"Cancer Discov"},{"key":"5646_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z et al (2023) A phase Ib\/II study of ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4:276\u2013293. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0205","journal-title":"Blood Cancer Discov"},{"key":"5646_CR33","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Pratz KW, Wei AH et al (2022) Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res Off J Am Assoc Cancer Res 28:5272\u20135279. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1183","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5646_CR34","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","volume":"5","author":"CA Lachowiez","year":"2021","unstructured":"Lachowiez CA, Loghavi S, Furudate K et al (2021) Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5:2173\u20132183. https:\/\/doi.org\/10.1182\/bloodadvances.2020004173","journal-title":"Blood Adv"},{"key":"5646_CR35","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E et al (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3:2911\u20132919. https:\/\/doi.org\/10.1182\/bloodadvances.2019000243","journal-title":"Blood Adv"},{"key":"5646_CR36","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1097\/HS9.0000000000000549","volume":"5","author":"J Feld","year":"2021","unstructured":"Feld J, Tremblay D, Dougherty M et al (2021) Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies. HemaSphere 5:e549. https:\/\/doi.org\/10.1097\/HS9.0000000000000549","journal-title":"HemaSphere"},{"key":"5646_CR37","doi-asserted-by":"publisher","first-page":"E154","DOI":"10.1002\/ajh.26122","volume":"96","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, Maiti A, DiNardo CD et al (2021) Decitabine and venetoclax for IDH1\/2-mutated acute myeloid leukemia. Am J Hematol 96:E154\u2013E157. https:\/\/doi.org\/10.1002\/ajh.26122","journal-title":"Am J Hematol"},{"key":"5646_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","volume":"13","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang X, Xu Y et al (2023) Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia. Blood Cancer J 13:155. https:\/\/doi.org\/10.1038\/s41408-023-00928-1","journal-title":"Blood Cancer J"},{"key":"5646_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M et al (2022) CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood 139:87\u2013103. https:\/\/doi.org\/10.1182\/blood.2020009680","journal-title":"Blood"},{"key":"5646_CR40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, K\u00f6hnke T et al (2020) Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer 1:826\u2013839. https:\/\/doi.org\/10.1038\/s43018-020-0103-x","journal-title":"Nat Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05646-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05646-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05646-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T06:08:37Z","timestamp":1710396517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05646-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["5646"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05646-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the West China Hospital Institutional Review Board and in accordance with the Helsinki declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}